ANAPTYSBIO, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount
ANAPTYSBIO, INC. (ANAB) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount of $0 for the 12-month period ending 2020-12-31, per its 10-K filed 2021-02-25.
Discontinued › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2021-02-25
- ANAPTYSBIO, INC. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2020 was $0.00.
- ANAPTYSBIO, INC. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2019 was $0.00, a 100.00% decline from fiscal 2018.
- ANAPTYSBIO, INC. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2018 was $63.00K, a 90.72% decline from fiscal 2017.
- ANAPTYSBIO, INC. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2017 was $679.00K, a 13.94% decline from fiscal 2016.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount 12 month |
|---|---|
| 2020-12-31 | $0.00 10-K · filed 2021-02-25 |
| 2019-12-31 | $0.00 10-K · filed 2021-02-25 |
| 2018-12-31 | $63.00K 10-K · filed 2021-02-25 |
| 2017-12-31 | $679.00K 10-K · filed 2020-03-02 |
| 2016-12-31 | $789.00K 10-K · filed 2019-02-28 |
| 2015-12-31 | $0.00 10-K · filed 2018-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |